Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New workshop aims to help chronic pain patients taper opioids safely

NCT ID NCT04902547

Symptom relief Sponsor: University of Manitoba Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a one-day educational workshop for people with chronic non-cancer pain who take high doses of opioids. The workshop, led by a team of doctors, psychologists, and pharmacists, provided information on opioid risks and taught coping strategies. Researchers wanted to see if it changed attitudes toward reducing opioid use and helped participants lower their doses safely. 26 people took part in the completed study.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Patient Education Workshop (behavioral intervention)
What this could lead to
If successful, this workshop could help people with chronic pain reduce their opioid doses safely, lowering risks of addiction and side effects.
What could go wrong
This is a small, completed study with only 26 participants. Results may not apply to everyone, and tapering opioids can be difficult for some.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

26 people

The number who actually took part.

Started

May 2021

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * CNCP on more than half the days in the previous 6 months * use of opioids for more than half the days in the previous 90 days * daily morphine equivalent dose equal to or greater than 50 mg * age 18 years or older * cognitive ability to understand questionnaires and participate in English only education sessions * minimum average numerical pain rating of 3/10 Exclusion Criteria: * Currently receiving ACT or CBT * previous experience with ACT within the past 12 months * significant uncontrolled depression with or without suicidal ideation * current psychosis * known or suspected opioid misuse/abuse based on a score of seven or greater on the Opioid Risk Tool * known or suspected opioid diversion based on previous clinician report and/or results of urine drug screen

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hyperalgesia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

agnosia Chronic Pain chronic pain syndrome Hyperalgesia opioid abuse

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hyperalgesia Opioid use Opioids; harmful use Pain, chronic

Contacts and locations

Locations

  • ACCESS River East

    Winnipeg, Manitoba, R3R 1K8, Canada

  • ACCESS Winnipeg West

    Winnipeg, Manitoba, Canada

  • Health Sciences Centre Pain Clinic

    Winnipeg, Manitoba, Canada

  • Pan Am Pain Clinic

    Winnipeg, Manitoba, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.